BCM
FOLD

Bayesian Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Bayesian Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,900
Closed -$162K – 663
2025
Q1 		$162K Sell
19,900
-47,000
-70% -$435K 0.03% 514
2024
Q4 		$630K Buy
66,900
+54,100
+423% +$562K 0.08% 323
2024
Q3 		$137K Buy
+12,800
New +$139K 0.02% 587
2024
Q2 		– Sell
-50,200
Closed -$591K – 866
2024
Q1 		$591K Buy
+50,200
New +$642K 0.06% 403
2023
Q1 		– Sell
-11,537
Closed -$141K – 897
2022
Q4 		$141K Buy
+11,537
New +$130K 0.02% 640
2021
Q2 		– Sell
-24,700
Closed -$244K – 485
2021
Q1 		$244K Buy
+24,700
New +$382K 0.06% 403
2020
Q1 		– Sell
-20,206
Closed -$197K – 836
2019
Q4 		$197K Sell
20,206
-2,794
-12% -$25.6K 0.03% 538
2019
Q3 		$184K Buy
+23,000
New +$250K 0.03% 456
2017
Q2 		– Sell
-17,500
Closed -$125K – 489
2017
Q1 		$125K Buy
17,500
+5,300
+43% +$33.5K 0.06% 372
2016
Q4 		$61K Buy
+12,200
New +$84.4K 0.02% 572

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bayesian Capital Management's FOLD Position: Q2 2025 in Review

Bayesian Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 19,900 shares — an estimated $162K sold.

Bayesian Capital Management first reported a position in FOLD in Q4 2016 and held it in 10 quarters. The position peaked at $630K in Q4 2024. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Bayesian Capital Management reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 19,900 Amicus Therapeutics shares in Q2 2025, an estimated $162K.
  • Bayesian Capital Management first reported a position in Amicus Therapeutics in Q4 2016 and held it in 10 quarters.
  • Bayesian Capital Management's Amicus Therapeutics position peaked at $630K in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.